North America Infertility Diagnostics Devices Market Report and Forecast 2025-2034

North America Infertility Diagnostics Devices Market Outlook

The global infertility diagnostics devices market size is expected to grow at a CAGR of 8.80% during the forecast period of 2025-2034, with North America holding a significant market share. The market is driven by the rising prevalence of infertility along with advancements in diagnostic technologies.

Key Takeaways

• In November 2023, Femasys Inc., secured an upfront investment of USD 6.85 million from PharmaCyte Biotech. The financing will support the commercialization of Femasys infertility-related products, including FemVue, which can help to check tubal infertility or blocked tubes in women. The increased access to such innovative diagnostic devices is likely to augment North America infertility diagnostics devices market share in the forecast years.

• Infertility is a common problem in the United States, with around 11% of women and 9% of men affected by this condition in their reproductive age. Rising infertility burden is likely to elevate market value in the forecast period.

• Intensive research efforts associated with infertility and its treatments are resulting in the development of advanced testing methods. This is are anticipated to boost market growth. In June 2023, researchers at the University of Alberta discovered two unique protein biomarkers that have the potential to provide a non-invasive diagnostic test for men.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

North America Infertility Diagnostics Devices Market Analysis

Infertility can be defined as a condition that impairs the body’s ability to reproduce. It can be caused due to issues with the reproductive system of either the male or female partner. In women, the most common cause of infertility includes irregular ovulation, obstructed fallopian tubes, and endometriosis whereas in men, sperm disorders are the common cause of infertility issues. Factors such as lifestyle changes, delayed childbearing, and rising incidence of conditions affecting fertility are contributing to the growing cases of infertility in the region. Heightened patient awareness surrounding infertility along with the reduced stigma attached to seeking treatments for the condition are expected to significantly drive the North America infertility diagnostics devices market demand in coming years.

Rising healthcare expenditure and insurance coverage for infertility treatments in North America are positively influencing the market landscape. Moreover, the increased prevalence of infertility issues in the region directly impacts the demand for infertility diagnostic services and devices. Recent data suggests that infertility is a common problem in the United States, with around 11% of women and 9% of men of child-bearing age affected by this condition. This sharp increase in infertility burden is likely to elevate market value in the forecast period.

The rising investment in the infertility diagnostics sector to address the growing demand for advanced diagnostic solutions is expected to fuel North America infertility diagnostics devices market growth. In November 2023, Femasys Inc., a United States-based biomedical company, secured an upfront investment of USD 6.85 million from PharmaCyte Biotech (a biotechnology company headquartered in the United States). The financing will support the commercialization of Femasys infertility-related products, FemaSeed and FemVue, as well as the development of a broad portfolio of other products. FemVue, the first FDA-cleared diagnostic device for fallopian tube assessment, can help to check for tubal infertility or blocked tubes in women. The increased access to such innovative diagnostic devices is likely to augment market size in the region.

Intensive research efforts associated with infertility and its treatments are resulting in the development of advanced testing methods, which are anticipated to significantly boost North America infertility diagnostics devices market value. In June 2023, a team of researchers at the University of Alberta (a public research university in Canada) discovered two proteins that are only found in viable sperms. These unique protein biomarkers have the potential to provide men with a non-invasive diagnostic test that can offer insights into whether in vitro fertilization can work in certain patients. The development of such innovative diagnostic tests with the ability to predict the success rate of surgery in infertile men is expected to accelerate market growth in coming years.

North America Infertility Diagnostics Devices Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

North America Infertility Diagnostics Devices Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Cook Group

• Vitrolife

• Thermo Fisher Scientific

• Hamilton Thorne LTD

• Esco Micro Pte Ltd

• Genea Limited

• IVFtech APS

• FUJIFILM Irvine Scientific

• The Baker Company Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Highlights of the Report